• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡啶并[2,3-]嘧啶-7(8)-酮:合成与生物医学应用。

Pyrido[2,3-]pyrimidin-7(8)-ones: Synthesis and Biomedical Applications.

机构信息

Grup de Química Farmacèutica, IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, E-08017 Barcelona, Spain.

出版信息

Molecules. 2019 Nov 16;24(22):4161. doi: 10.3390/molecules24224161.

DOI:10.3390/molecules24224161
PMID:31744155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6891647/
Abstract

Pyrido[2,3-]pyrimidines () are a type of privileged heterocyclic scaffolds capable of providing ligands for several receptors in the body. Among such structures, our group and others have been particularly interested in pyrido[2,3-]pyrimidine-7(8)-ones () due to the similitude with nitrogen bases present in DNA and RNA. Currently there are more than 20,000 structures described which correspond to around 2900 references (half of them being patents). Furthermore, the number of references containing compounds of general structure have increased almost exponentially in the last 10 years. The present review covers the synthetic methods used for the synthesis of pyrido[2,3-]pyrimidine-7(8)-ones (), both starting from a preformed pyrimidine ring or a pyridine ring, and the biomedical applications of such compounds.

摘要

吡啶并[2,3-]嘧啶类化合物()是一类具有特权杂环结构的化合物,能够为体内的多个受体提供配体。在这些结构中,我们的团队和其他团队对吡啶并[2,3-]嘧啶-7(8)-酮类化合物()特别感兴趣,因为它们与 DNA 和 RNA 中存在的氮碱基相似。目前已经描述了超过 20,000 种结构,对应约 2900 个参考文献(其中一半是专利)。此外,在过去 10 年中,包含一般结构化合物的参考文献数量几乎呈指数级增长。本综述涵盖了用于合成吡啶并[2,3-]嘧啶-7(8)-酮类化合物()的合成方法,既可以从预先形成的嘧啶环或吡啶环开始,也可以从预先形成的嘧啶环或吡啶环开始,还涵盖了此类化合物的生物医学应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/517d68795e77/molecules-24-04161-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/02e8d803d06b/molecules-24-04161-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/ccec66b3fa11/molecules-24-04161-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/0ea7c70364e6/molecules-24-04161-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/a998fc8f9f92/molecules-24-04161-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/c1816897d34e/molecules-24-04161-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3ca9c4a7f3be/molecules-24-04161-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/e9bbf42f1951/molecules-24-04161-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/e88544220c6f/molecules-24-04161-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/d51acdc9c2fa/molecules-24-04161-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/816ba582fb14/molecules-24-04161-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3282bef304ae/molecules-24-04161-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/74d15f2cdb8e/molecules-24-04161-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/cf9db1b9c6f7/molecules-24-04161-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/6725b0f090f4/molecules-24-04161-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3dddd224de09/molecules-24-04161-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/e3025f4a1907/molecules-24-04161-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/08d0ba7230c2/molecules-24-04161-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3107e54b5c97/molecules-24-04161-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/5b6604d3472c/molecules-24-04161-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/4841958dbf67/molecules-24-04161-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/45553247644d/molecules-24-04161-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/517d68795e77/molecules-24-04161-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/02e8d803d06b/molecules-24-04161-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/ccec66b3fa11/molecules-24-04161-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/0ea7c70364e6/molecules-24-04161-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/a998fc8f9f92/molecules-24-04161-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/c1816897d34e/molecules-24-04161-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3ca9c4a7f3be/molecules-24-04161-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/e9bbf42f1951/molecules-24-04161-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/e88544220c6f/molecules-24-04161-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/d51acdc9c2fa/molecules-24-04161-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/816ba582fb14/molecules-24-04161-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3282bef304ae/molecules-24-04161-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/74d15f2cdb8e/molecules-24-04161-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/cf9db1b9c6f7/molecules-24-04161-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/6725b0f090f4/molecules-24-04161-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3dddd224de09/molecules-24-04161-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/e3025f4a1907/molecules-24-04161-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/08d0ba7230c2/molecules-24-04161-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/3107e54b5c97/molecules-24-04161-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/5b6604d3472c/molecules-24-04161-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/4841958dbf67/molecules-24-04161-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/45553247644d/molecules-24-04161-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3908/6891647/517d68795e77/molecules-24-04161-g022.jpg

相似文献

1
Pyrido[2,3-]pyrimidin-7(8)-ones: Synthesis and Biomedical Applications.吡啶并[2,3-]嘧啶-7(8)-酮:合成与生物医学应用。
Molecules. 2019 Nov 16;24(22):4161. doi: 10.3390/molecules24224161.
2
Concise synthesis of rare pyrido[1,2-a]pyrimidin-2-ones and related nitrogen-rich bicyclic scaffolds with a ring-junction nitrogen.含环连接氮的罕见吡啶并[1,2-a]嘧啶-2-酮及相关富氮双环骨架的简洁合成。
Org Biomol Chem. 2016 Jan 21;14(3):1031-8. doi: 10.1039/c5ob01784j. Epub 2015 Dec 3.
3
Synthesis and biological evaluation of some novel pyrido[1,2-a]pyrimidin-4-ones as antimalarial agents.某些新型吡啶并[1,2-a]嘧啶-4-酮作为抗疟剂的合成及生物学评价
Eur J Med Chem. 2014 May 22;79:422-35. doi: 10.1016/j.ejmech.2014.04.031. Epub 2014 Apr 13.
4
A new and practical method for the synthesis of 6-aryl-5,6-dihydropyrido[2,3-d]pyrimidine-4,7(₃Η,8Η)-diones.一种新型实用的 6-芳基-5,6-二氢哒嗪并[2,3-d]嘧啶-4,7(3H,8H)-二酮的合成方法。
Mol Divers. 2013 Aug;17(3):525-36. doi: 10.1007/s11030-013-9450-1. Epub 2013 May 26.
5
p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.p38丝裂原活化蛋白激酶抑制剂。第3部分:3,4 - 二氢嘧啶并[4,5 - d]嘧啶 - 2 - 酮和3,4 - 二氢吡啶并[4,3 - d]嘧啶 - 2 - 酮的构效关系
Bioorg Med Chem Lett. 2006 Aug 15;16(16):4400-4. doi: 10.1016/j.bmcl.2006.05.045. Epub 2006 Jun 5.
6
Synthesis of 4-substituted pyrido[2,3-d]pyrimidin-4(1H)-one as analgesic and anti-inflammatory agents.作为镇痛和抗炎剂的4-取代吡啶并[2,3-d]嘧啶-4(1H)-酮的合成
Bioorg Med Chem Lett. 2009 Jul 1;19(13):3392-7. doi: 10.1016/j.bmcl.2009.05.044. Epub 2009 May 18.
7
Expanding the Diversity at the C-4 Position of Pyrido[2,3-]pyrimidin-7(8)-ones to Achieve Biological Activity against ZAP-70.扩展吡啶并[2,3 - ]嘧啶 - 7(8) - 酮C - 4位的多样性以实现对ZAP - 70的生物活性。
Pharmaceuticals (Basel). 2021 Dec 15;14(12):1311. doi: 10.3390/ph14121311.
8
Synthesis of pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-ones as potential antimicrobial agents.嘧啶并[2,3-d][1,2,4]三唑并[4,3-a]嘧啶-5-酮类化合物的合成及其作为潜在抗菌剂的研究。
Arch Pharm Res. 2013 May;36(5):564-72. doi: 10.1007/s12272-013-0045-2. Epub 2013 Feb 28.
9
Versatile solid-phase synthesis of trisubstituted 1H-pyrido[2,3-d]pyrimidin-4-ones and related heterocycles.三取代1H-吡啶并[2,3-d]嘧啶-4-酮及相关杂环的通用固相合成
J Comb Chem. 2005 Jan-Feb;7(1):96-8. doi: 10.1021/cc049921m.
10
Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.6-(2,6-二氯苯基)-8-甲基-2-(苯氨基)吡啶并[2,3-d]嘧啶-7(6H)-酮的构效关系:向选择性 Abl 抑制剂发展。
Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. doi: 10.1016/j.bmcl.2009.10.085. Epub 2009 Oct 23.

引用本文的文献

1
Overcoming Resistance in Cancer Therapy: Computational Exploration of PIK3CA Mutations, Unveiling Novel Non-Toxic Inhibitors, and Molecular Insights Into Targeting PI3Kα.克服癌症治疗中的耐药性:PIK3CA突变的计算探索、新型无毒抑制剂的发现以及靶向PI3Kα的分子见解
Bioinform Biol Insights. 2024 Aug 19;18:11779322241269386. doi: 10.1177/11779322241269386. eCollection 2024.
2
Synthesis, Herbicidal Activity, Mode of Action, and In Silico Analysis of Novel Pyrido[2,3-]pyrimidine Compounds.新型吡啶并[2,3-]嘧啶类化合物的合成、除草活性、作用方式及计算机模拟分析。
Molecules. 2023 Oct 31;28(21):7363. doi: 10.3390/molecules28217363.
3

本文引用的文献

1
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.用于脑胶质瘤的穿透性 CDK4/6 抑制剂的设计。
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2294-2301. doi: 10.1016/j.bmcl.2019.06.021. Epub 2019 Jun 26.
2
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.第三代 CDK 抑制剂:帕博西尼、瑞博西利和阿贝西利的合成及结合模式综述。
Eur J Med Chem. 2019 Jun 15;172:143-153. doi: 10.1016/j.ejmech.2019.03.064. Epub 2019 Apr 4.
3
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Antiproliferative activity of antimicrobial peptides and bioactive compounds from the mangrove .
来自红树林的抗菌肽和生物活性化合物的抗增殖活性
Front Microbiol. 2023 Feb 17;14:1096826. doi: 10.3389/fmicb.2023.1096826. eCollection 2023.
4
Medicinal chemistry perspective of pyrido[2,3-]pyrimidines as anticancer agents.吡啶并[2,3 - ]嘧啶作为抗癌剂的药物化学视角。
RSC Adv. 2023 Feb 28;13(10):6872-6908. doi: 10.1039/d3ra00056g. eCollection 2023 Feb 21.
5
In Silico Drug Repurposing Framework Predicts Repaglinide, Agomelatine and Protokylol as TRPV1 Modulators with Analgesic Activity.计算机辅助药物重定位框架预测瑞格列奈、阿戈美拉汀和丙卡特罗为具有镇痛活性的瞬时受体电位香草酸亚型1(TRPV1)调节剂。
Pharmaceutics. 2022 Nov 22;14(12):2563. doi: 10.3390/pharmaceutics14122563.
6
A convenient catalytic method for preparation of new tetrahydropyrido[2,3-]pyrimidines a cooperative vinylogous anomeric based oxidation.一种制备新型四氢吡啶并[2,3 - ]嘧啶的便捷催化方法——基于协同烯醇式异头碳氧化反应。
RSC Adv. 2022 Nov 30;12(53):34282-34292. doi: 10.1039/d2ra05655k. eCollection 2022 Nov 29.
7
Expanding the Diversity at the C-4 Position of Pyrido[2,3-]pyrimidin-7(8)-ones to Achieve Biological Activity against ZAP-70.扩展吡啶并[2,3 - ]嘧啶 - 7(8) - 酮C - 4位的多样性以实现对ZAP - 70的生物活性。
Pharmaceuticals (Basel). 2021 Dec 15;14(12):1311. doi: 10.3390/ph14121311.
8
1,6-Naphthyridin-2(1)-ones: Synthesis and Biomedical Applications.1,6-萘啶-2(1)-酮:合成与生物医学应用
Pharmaceuticals (Basel). 2021 Oct 9;14(10):1029. doi: 10.3390/ph14101029.
9
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design.吡啶和二氢吡啶支架在药物设计中的作用不断扩大。
Drug Des Devel Ther. 2021 Oct 13;15:4289-4338. doi: 10.2147/DDDT.S329547. eCollection 2021.
10
Synthesis and cytotoxic evaluation of some novel 3-[2-(2-phenyl-thiazol-4-yl)-ethyl]-3H-pyrido[2,3-d]pyrimidin-4-one derivatives.一些新型3-[2-(2-苯基-噻唑-4-基)-乙基]-3H-吡啶并[2,3-d]嘧啶-4-酮衍生物的合成与细胞毒性评价
Res Pharm Sci. 2021 Aug 19;16(5):455-463. doi: 10.4103/1735-5362.323912. eCollection 2021 Oct.
大量整合的基因组特征患者来源异种移植物突出了三阴性乳腺癌的异质性。
Int J Cancer. 2019 Oct 1;145(7):1902-1912. doi: 10.1002/ijc.32266. Epub 2019 Apr 4.
4
Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells.帕博西尼与氟维司群协同作用调节乳腺癌细胞的中心碳代谢。
Metabolites. 2019 Jan 2;9(1):7. doi: 10.3390/metabo9010007.
5
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure.TAS-120 癌症靶点结合:定义反应性并揭示第一个成纤维细胞生长因子受体 1(FGFR1)不可逆结构。
ChemMedChem. 2019 Feb 19;14(4):494-500. doi: 10.1002/cmdc.201800719. Epub 2019 Jan 14.
6
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.在胰腺癌细胞中靶向视网膜母细胞瘤蛋白磷酸化与 EGFR 抑制的联合作用。
Int J Oncol. 2019 Feb;54(2):527-536. doi: 10.3892/ijo.2018.4658. Epub 2018 Dec 7.
7
Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.CDK4/6 抑制剂给药后大鼠的肠道毒性与其主要药理学无关。
Mol Cancer Ther. 2019 Feb;18(2):257-266. doi: 10.1158/1535-7163.MCT-18-0734. Epub 2018 Nov 6.
8
Expedient multicomponent synthesis of a small library of some novel highly substituted pyrido[2,3-d]pyrimidine derivatives mediated and promoted by deep eutectic solvent and in vitro and quantum mechanical study of their antibacterial and antifungal activities.通过深共熔溶剂介导和促进的一些新型高取代吡啶并[2,3-d]嘧啶衍生物的小库的便捷多组分合成及其体外抗菌和抗真菌活性的量子力学研究。
Mol Divers. 2019 Feb;23(1):93-105. doi: 10.1007/s11030-018-9859-7. Epub 2018 Jul 19.
9
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT.发现手性二氢吡啶并嘧啶酮类化合物作为有效的、选择性的和口服生物利用度的 AKT 抑制剂。
Bioorg Med Chem Lett. 2018 Jun 1;28(10):1887-1891. doi: 10.1016/j.bmcl.2018.03.092. Epub 2018 Apr 2.
10
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.帕纳替尼通过多激酶抑制作用显示出对卵巢小细胞癌伴高钙血症(SCCOHT)的强大抗肿瘤活性。
Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. doi: 10.1158/1078-0432.CCR-17-1928. Epub 2018 Feb 9.